Efficacy analysis in our study showed a median TTP of 61 months, and an overall response rate (ORR) of 87% for the whole cohort; in terms of histotypes, patients with indolent lymphoma or MCL had superior TTP as compared to CLL patients, with a trend towards improved outcome for LPL/WM at multivariate analysis. The gene discussed is LPL; the disease is B-cell chronic lymphocytic leukemia.